Bioisosterism in Drug Discovery and Development - An Overview

被引:24
|
作者
Jayashree, B. S. [1 ]
Nikhil, P. Sai [1 ]
Paul, Soumyajeet [1 ]
机构
[1] Manipal Acad Higher Educ, Dept Pharmaceut Chem, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India
关键词
Bioisosterism; lead; enzyme inhibition; scaffold hopping; antimetabolites; benzopyrones; carbostyrils; MOLECULAR MODIFICATION; IN-VITRO; AGENTS; ANTICANCER; INHIBITORS; ISOSTERISM; CHALCONES; SCAFFOLD; DESIGN; MOIETY;
D O I
10.2174/1573406418666220127124228
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Bioisosterism is a unique approach used by medicinal chemists for the reasonable modification of lead compounds into safer, more clinically effective, economical, and therapeutically attractive drugs. It is one of the most crucial lead modification tools, widely applied in the field of rational drug design to amplify the desired activity and eliminate undesirable properties, thus facilitating the optimization of pharmacokinetic profile and achievement of target selectivity. This review demonstrates the importance of bioisosterism in the process of drug discovery and development and highlights its relevance in the molecular evolution of many classes of drugs such as antibacterial sulfonamides, anticancer drugs, antivirals, antifungals, anthelmintics, local anesthetics, barbiturates, antidepressants, antihistamines, proton pump inhibitors and work carried out by our team of researchers. The role of bioisosterism as a strategy to achieve inhibition of enzymes such as thymidylate synthase, DNA polymerase, reverse transcriptase and several others has also been pointed out. There are no limits to the classes of drugs where bioisosterism has been successfully applied.
引用
收藏
页码:915 / 925
页数:11
相关论文
共 50 条
  • [31] An overview of chemotherapeutic targets for antimalarial drug discovery
    Olliaro, PL
    Yuthavong, Y
    PHARMACOLOGY & THERAPEUTICS, 1999, 81 (02) : 91 - 110
  • [32] Electrophilic warheads in covalent drug discovery: an overview
    Peczka, Nikolett
    Orgovan, Zoltan
    Abranyi-Balogh, Peter
    Keseru, Gyorgy Miklos
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (04) : 413 - 422
  • [33] An overview of PROTACs: a promising drug discovery paradigm
    Liu, Zi
    Hu, Mingxing
    Yang, Yu
    Du, Chenghao
    Zhou, Haoxuan
    Liu, Chengyali
    Chen, Yuanwei
    Fan, Lei
    Ma, Hongqun
    Gong, Youling
    Xie, Yongmei
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
  • [34] Editorial overview - Can drug discovery be industrialized?
    Gund, P
    Maliski, E
    Brown, F
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (03) : 283 - 284
  • [35] Drug metabolism in drug discovery and development
    Zhang, Zhoupeng
    Tang, Wei
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (05) : 721 - 732
  • [36] Editorial overview: New concept in drug discovery
    Cavalli, Andrea
    Ciulli, Alessio
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2024, 88
  • [37] Editorial overview - Backup programs in drug discovery
    Greenlee, WJ
    Desai, M
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2006, 9 (04) : 412 - 413
  • [38] Drug metabolism in drug discovery and development
    Zhoupeng Zhang
    Wei Tang
    Acta Pharmaceutica Sinica B, 2018, 8 (05) : 721 - 732
  • [39] Biomarker development in drug discovery and development
    Shinagawa, Akira
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 54P - 54P
  • [40] Antiviral drug discovery and development
    Nature Reviews Drug Discovery, 2007, 6 : 1019 - 1019